XML 63 R46.htm IDEA: XBRL DOCUMENT
v3.24.1

Third Party Agreements - Additional Information (Details) - USD ($) $ in Thousands |  | 12 Months Ended
--- | --- | ---
Jan. 28, 2022 | Dec. 31, 2023 | Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Research and development in process 1 |  | $ 1,000 |
License agreement termination description |  | twelve (12) years |
Payment from Regeneron for exercise of its option to license exclusive rights |  | $ 4 | $ 1,315
Regeneron Pharmaceuticals, Inc. |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Non refundable upfront payment received |  | 25,000 |
Additional payment for research funding received |  | 20,000 |
Exercise Fee Paid | $ 20,000 | 20,000 |
Revenue recognized |  | 5,000 |
Licence agreement additional revenue recognised |  | 25,000 |
Regeneron Pharmaceuticals, Inc. | Maximum [Member] |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Licence agreement additional amount payable of option exercise fees |  | $ 80,000 |

X
- Definition Exercise fee paid. + References No definition available. + Details
Name: | acet_ExerciseFeePaid
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Additional amount payable of option exercise fees. + References No definition available. + Details
Name: | acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Licence agreement additional revenue recognised. + References No definition available. + Details
Name: | acet_LicenceAgreementAdditionalRevenueRecognised
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Additional payment for research funding received. + References No definition available. + Details
Name: | acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License agreement termination description. + References No definition available. + Details
Name: | acet_LicenseAgreementTerminationDescription
Namespace Prefix: | acet_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non refundable upfront payment received. + References No definition available. + Details
Name: | acet_NonRefundableUpfrontPaymentReceived
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and development in process 1 + References No definition available. + Details
Name: | acet_ResearchAndDevelopmentInProcess1
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash inflow from exercise of option under share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A + Details
Name: | us-gaap_ProceedsFromStockOptionsExercised
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |